In this episode of “Blood Cancer Talks,” Angela Dispenzieri, MD, of the Mayo Clinic, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD, to discuss the management of newly diagnosed light chain (AL) amyloidosis.
Dr. Dispenzieri and the hosts discussed the following topics:
- The ANDROMEDA trial, which evaluated Dara-VCD versus VCD
- The Mayo 2004 and 2012 staging systems
- The optimal use of tissue biopsy
- Hematologic and cardiac response criteria in AL amyloidosis
- Venetoclax in relapsed or refractory AL amyloidosis
- How to treat AL amyloidosis
This podcast originally appeared on Blood Cancer Talks.